Protalix Biotherapeutics Net Worth
Protalix Biotherapeutics Net Worth Breakdown | PLX |
Protalix Biotherapeutics Net Worth Analysis
Protalix Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Protalix Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Protalix Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Protalix Biotherapeutics' net worth analysis. One common approach is to calculate Protalix Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Protalix Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Protalix Biotherapeutics' net worth. This approach calculates the present value of Protalix Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Protalix Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Protalix Biotherapeutics' net worth. This involves comparing Protalix Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Protalix Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Protalix Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protalix Biotherapeutics' net worth research are outlined below:
| Protalix Biotherapeutics generated a negative expected return over the last 90 days | |
| Protalix Biotherapeutics has high historical volatility and very poor performance | |
| Protalix Biotherapeutics may become a speculative penny stock | |
| Latest headline from gurufocus.com: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief ... |
Protalix Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Protalix Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protalix Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Protalix Biotherapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 127.37 M.Market Cap |
|
Project Protalix Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.08 | 0.09 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.06 |
When accessing Protalix Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Protalix Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Protalix Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Check Protalix Biotherapeutics' Beneish M Score to see the likelihood of Protalix Biotherapeutics' management manipulating its earnings.
Evaluate Protalix Biotherapeutics' management efficiency
Protalix Biotherapeutics has Return on Asset of 0.0353 % which means that on every $100 spent on assets, it made $0.0353 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1042 %, implying that it generated $0.1042 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.09 in 2025, whereas Return On Equity is likely to drop 0.06 in 2025. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.5 M in 2025, whereas Total Assets are likely to drop slightly above 52.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.60 | 0.84 | |
| Tangible Book Value Per Share | 0.60 | 0.84 | |
| Enterprise Value Over EBITDA | 18.73 | 19.67 | |
| Price Book Value Ratio | 3.16 | 3.00 | |
| Enterprise Value Multiple | 18.73 | 19.67 | |
| Price Fair Value | 3.16 | 3.00 | |
| Enterprise Value | 122.1 M | 116 M |
The decision-making processes within Protalix Biotherapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 1.6375 | Revenue | Quarterly Revenue Growth 1.698 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protalix Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protalix Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protalix Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protalix Biotherapeutics time-series forecasting models is one of many Protalix Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protalix Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Protalix Biotherapeutics Earnings per Share Projection vs Actual
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.